Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.
Francisco Javier RedondoJuan Fernando PadínJose Ramon Muñoz-RodriguezLeticia Serrano-OviedoPilar López-JuárezMaría Lourdes Porras LealFrancisco Javier González GascaMarta Rodríguez MartínezRaúl Pérez SerranoAbraham Sánchez CadenaNatalia Bejarano-RamírezConstanza Muñoz HorneroJosé Ramón Barberá FarréInmaculada Domínguez-QuesadaMaría A Sepúlveda BerrocalMaría Dolores Villegas Fernández-InfantesMaría Isabel Manrique RomoÁngel Parra CominoJose Manuel Perez-OrtizFrancisco Javier Gómez-Romeronull nullPublished in: European journal of clinical investigation (2022)
Inhaled aprotinin may improve standard treatment and clinical outcomes in hospitalized patients with COVID-19, resulting in a shorter treatment time and hospitalization compared with the placebo group. The administration of aprotinin was safe.